CN113509439A - Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor - Google Patents
Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor Download PDFInfo
- Publication number
- CN113509439A CN113509439A CN202110784259.XA CN202110784259A CN113509439A CN 113509439 A CN113509439 A CN 113509439A CN 202110784259 A CN202110784259 A CN 202110784259A CN 113509439 A CN113509439 A CN 113509439A
- Authority
- CN
- China
- Prior art keywords
- self
- delivery system
- combination
- emulsifier
- emulsifying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 57
- 239000003814 drug Substances 0.000 title claims abstract description 26
- 208000007433 Lymphatic Metastasis Diseases 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000463 material Substances 0.000 claims abstract description 37
- 150000002632 lipids Chemical class 0.000 claims abstract description 28
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 22
- 239000002955 immunomodulating agent Substances 0.000 claims abstract description 19
- 229940121354 immunomodulator Drugs 0.000 claims abstract description 19
- 230000002584 immunomodulator Effects 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 13
- 239000007957 coemulsifier Substances 0.000 claims abstract description 12
- 210000002865 immune cell Anatomy 0.000 claims abstract description 11
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 59
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 57
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 55
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 54
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 54
- 229940074393 chlorogenic acid Drugs 0.000 claims description 54
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 54
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 54
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 21
- 210000004027 cell Anatomy 0.000 claims description 15
- 208000032839 leukemia Diseases 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 238000005303 weighing Methods 0.000 claims description 14
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 13
- 239000003921 oil Substances 0.000 claims description 13
- 235000019198 oils Nutrition 0.000 claims description 13
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 12
- 229960003511 macrogol Drugs 0.000 claims description 12
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 12
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 11
- 239000002202 Polyethylene glycol Substances 0.000 claims description 11
- 201000007983 brain glioma Diseases 0.000 claims description 11
- 125000005456 glyceride group Chemical group 0.000 claims description 11
- 201000005202 lung cancer Diseases 0.000 claims description 11
- 208000020816 lung neoplasm Diseases 0.000 claims description 11
- 229920001223 polyethylene glycol Polymers 0.000 claims description 11
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 9
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 9
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims description 8
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims description 8
- 229940093471 ethyl oleate Drugs 0.000 claims description 8
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 7
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 claims description 6
- UFCLZKMFXSILNL-RVXRWRFUSA-N 4,5-di-O-caffeoylquinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)O)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 UFCLZKMFXSILNL-RVXRWRFUSA-N 0.000 claims description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 6
- 230000001926 lymphatic effect Effects 0.000 claims description 6
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims description 6
- 229940049964 oleate Drugs 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 210000004324 lymphatic system Anatomy 0.000 claims description 5
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 claims description 5
- WECGLUPZRHILCT-GSNKCQISSA-N 1-linoleoyl-sn-glycerol Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OC[C@@H](O)CO WECGLUPZRHILCT-GSNKCQISSA-N 0.000 claims description 4
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000003078 antioxidant effect Effects 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 235000019864 coconut oil Nutrition 0.000 claims description 4
- 239000003240 coconut oil Substances 0.000 claims description 4
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 claims description 4
- 210000002540 macrophage Anatomy 0.000 claims description 4
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 4
- 210000000822 natural killer cell Anatomy 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 4
- KRZBCHWVBQOTNZ-UHFFFAOYSA-N (-) 3,5-dicaffeoyl-muco-quinic acid Natural products OC1C(OC(=O)C=CC=2C=C(O)C(O)=CC=2)CC(O)(C(O)=O)CC1OC(=O)C=CC1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-UHFFFAOYSA-N 0.000 claims description 3
- KRZBCHWVBQOTNZ-RDJMKVHDSA-M (-)-3,5-Dicaffeoyl quinic acid Natural products O([C@@H]1CC(O)(C[C@H](C1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C([O-])=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-RDJMKVHDSA-M 0.000 claims description 3
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 3
- SLKDGVPOSSLUAI-PGUFJCEWSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCCCCCCCCCC SLKDGVPOSSLUAI-PGUFJCEWSA-N 0.000 claims description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 3
- ZNQVEEAIQZEUHB-UHFFFAOYSA-N 2-ethoxyethanol Chemical compound CCOCCO ZNQVEEAIQZEUHB-UHFFFAOYSA-N 0.000 claims description 3
- UFCLZKMFXSILNL-AALYGJCLSA-N 3,4-Dicaffeoylquinic acid Natural products O=C(O[C@@H]1[C@H](OC(=O)/C=C/c2cc(O)c(O)cc2)C[C@](O)(C(=O)O)C[C@@H]1O)/C=C/c1cc(O)c(O)cc1 UFCLZKMFXSILNL-AALYGJCLSA-N 0.000 claims description 3
- KRZBCHWVBQOTNZ-PSEXTPKNSA-N 3,5-di-O-caffeoyl quinic acid Chemical compound O([C@@H]1C[C@](O)(C[C@H]([C@@H]1O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 KRZBCHWVBQOTNZ-PSEXTPKNSA-N 0.000 claims description 3
- GYFFKZTYYAFCTR-JUHZACGLSA-N 4-O-trans-caffeoylquinic acid Chemical compound O[C@@H]1C[C@](O)(C(O)=O)C[C@@H](O)[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-JUHZACGLSA-N 0.000 claims description 3
- GYFFKZTYYAFCTR-UHFFFAOYSA-N 5-O-(6'-O-galloyl)-beta-D-glucopyranosylgentisic acid Natural products OC1CC(O)(C(O)=O)CC(O)C1OC(=O)C=CC1=CC=C(O)C(O)=C1 GYFFKZTYYAFCTR-UHFFFAOYSA-N 0.000 claims description 3
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- GYFFKZTYYAFCTR-LMRQPLJMSA-N cryptochlorogenic acid Natural products O[C@H]1C[C@@](O)(C[C@H](O)[C@H]1OC(=O)C=Cc2ccc(O)c(O)c2)C(=O)O GYFFKZTYYAFCTR-LMRQPLJMSA-N 0.000 claims description 3
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 3
- 239000008344 egg yolk phospholipid Substances 0.000 claims description 3
- 229940068998 egg yolk phospholipid Drugs 0.000 claims description 3
- FMMOOAYVCKXGMF-MURFETPASA-N ethyl linoleate Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(=O)OCC FMMOOAYVCKXGMF-MURFETPASA-N 0.000 claims description 3
- 229940031016 ethyl linoleate Drugs 0.000 claims description 3
- 239000000945 filler Substances 0.000 claims description 3
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 3
- 235000020778 linoleic acid Nutrition 0.000 claims description 3
- FMMOOAYVCKXGMF-UHFFFAOYSA-N linoleic acid ethyl ester Natural products CCCCCC=CCC=CCCCCCCCC(=O)OCC FMMOOAYVCKXGMF-UHFFFAOYSA-N 0.000 claims description 3
- 230000003204 osmotic effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 3
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 239000008347 soybean phospholipid Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- GNSDEDOVXZDMKM-UHFFFAOYSA-N 1,2-didecanoylglycerol Chemical compound CCCCCCCCCC(=O)OCC(CO)OC(=O)CCCCCCCCC GNSDEDOVXZDMKM-UHFFFAOYSA-N 0.000 claims description 2
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 claims description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 2
- 235000010469 Glycine max Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 2
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims description 2
- 239000000022 bacteriostatic agent Substances 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- 229940106189 ceramide Drugs 0.000 claims description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000000536 complexating effect Effects 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 235000013601 eggs Nutrition 0.000 claims description 2
- 230000001394 metastastic effect Effects 0.000 claims description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 claims description 2
- 229960004245 silymarin Drugs 0.000 claims description 2
- 235000017700 silymarin Nutrition 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- 230000002519 immonomodulatory effect Effects 0.000 claims 4
- 229940049918 linoleate Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 abstract description 14
- 210000001165 lymph node Anatomy 0.000 abstract description 13
- 150000001875 compounds Chemical class 0.000 abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 10
- 210000002751 lymph Anatomy 0.000 abstract description 8
- 239000012530 fluid Substances 0.000 abstract description 4
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002496 gastric effect Effects 0.000 abstract description 3
- 230000001900 immune effect Effects 0.000 abstract description 3
- 239000007908 nanoemulsion Substances 0.000 abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 230000000694 effects Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 229940083466 soybean lecithin Drugs 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 238000011065 in-situ storage Methods 0.000 description 7
- 238000011068 loading method Methods 0.000 description 7
- 238000007865 diluting Methods 0.000 description 6
- 230000009401 metastasis Effects 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- -1 chlorogenic acid lipid Chemical class 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 238000001959 radiotherapy Methods 0.000 description 5
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 101150013553 CD40 gene Proteins 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000013558 reference substance Substances 0.000 description 4
- 238000002271 resection Methods 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000001365 lymphatic vessel Anatomy 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005760 tumorsuppression Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CWVRJTMFETXNAD-GMZLATJGSA-N 5-Caffeoyl quinic acid Natural products O[C@H]1C[C@](O)(C[C@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-GMZLATJGSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 238000011765 DBA/2 mouse Methods 0.000 description 2
- 208000006552 Lewis Lung Carcinoma Diseases 0.000 description 2
- 206010027457 Metastases to liver Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 1
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 1
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 206010059282 Metastases to central nervous system Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- FGDQGIKMWOAFIK-UHFFFAOYSA-N acetonitrile;phosphoric acid Chemical compound CC#N.OP(O)(O)=O FGDQGIKMWOAFIK-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000719 anti-leukaemic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 229920000736 dendritic polymer Polymers 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000010812 external standard method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- RIHVNUUUFKBTIN-UHFFFAOYSA-N furan-2-carbaldehyde;propane-1,2,3-triol Chemical compound OCC(O)CO.O=CC1=CC=CO1 RIHVNUUUFKBTIN-UHFFFAOYSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000008088 immune pathway Effects 0.000 description 1
- 229940124644 immune regulator Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000011242 molecular targeted therapy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical group CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to an application of a self-emulsifying delivery system in preparing an oral medicament for treating lymphatic metastasis tumor, wherein the self-emulsifying delivery system comprises an oil phase, an emulsifier, a co-emulsifier and an immunomodulator lipid material compound. The self-emulsifying delivery system is a lipid carrier mainly composed of an oil phase, an emulsifying agent and an auxiliary emulsifying agent, can be diluted by gastrointestinal fluid and emulsified into an oil-in-water (o/w) nano-emulsion after being taken orally, is targeted and gathered in mesenteric lymph nodes through a lymph transport path, activates immune cells in the mesenteric lymph nodes, and finally exerts the immune effect of resisting tumors (particularly lymphatic metastasis tumors). The self-emulsifying delivery system can not only improve the compliance of patients, but also has more treatment advantages on tumors which are transferred by lymph, especially tumors which are sensitive to tumor immunotherapy.
Description
Technical Field
The invention belongs to the technical field of biological medicines, relates to a novel pharmaceutical application of a self-emulsifying delivery system, and particularly relates to an application of the self-emulsifying delivery system in preparing an oral medicine for treating lymphatic metastasis tumors.
Background
Tumor metastasis is a process in which tumor cells are shed from primary foci, migrate to other parts through lymphatic vessels or blood vessels, and continue to grow, and is the leading cause of death of tumor patients. Metastasis of tumor cells tends to be somewhat directional, like "seeds", migrating selectively towards a microenvironment more suitable for their growth. For example, breast cancer is susceptible to lung, bone and brain metastases, colon cancer is susceptible to lung and liver metastases, and pancreatic cancer is susceptible to liver metastases. Tumor metastasis is mainly divided into two pathways, namely hematogenous metastasis and lymphatic metastasis. Malignant tumors are more prone to metastasize via the lymphatic system, which is thus the primary route of spread for many solid tumors (e.g., melanoma, breast cancer, etc.), than transvascular metastasis. The main reasons are as follows: (1) compared with the vascular structure, the endothelial cells of the lymphatic vessels are loosely connected, and the basement membrane is not complete enough, so that the tumor cells can enter the lymphatic vessels more easily; (2) the flow rate of lymph fluid is slow, so that tumor cells can survive in the lymphatic system more easily; (3) the serum-free lymphatic environment allows the cells to have higher viability in the lymphatic fluid.
Surgical resection, chemotherapy, radiotherapy and tumor immunotherapy are four major current therapies for tumor treatment. However, when the tumor is metastasized, there may be multiple metastases (e.g., lymph node metastasis), and it is difficult to eradicate all metastases by surgical resection and radiotherapy, with the resulting damage to the patient being greater. While chemotherapy drugs or immunotherapy drugs which are systemically administered are often resident in blood or visceral organs and are difficult to enter the lymphatic system, which seriously affects the treatment effect on lymphatic metastases. Therefore, inhibiting the lymphatic metastasis of tumors is one of the major research points in the field of tumor therapy today. For caffeoylquinic acid immunomodulators such as chlorogenic acid, good tumor immunotherapy effect is difficult to be achieved by oral administration, and only injection administration can be adopted clinically. However, the stimulation effect of injection administration on immune cells such as T cells, DC cells, macrophages and the like is not very ideal, so that the long-time frequent injection and the intramuscular injection for several months and once a day are needed clinically, so that the patient compliance is poor, and the clinical treatment and application are limited.
Oral administration has superior compliance compared to invasive administration by injection. However, it is difficult for caffeoylquinic acid immunomodulators to exhibit good immunotherapeutic effects when administered orally. According to the recognition of those skilled in the art, even if the bioavailability is increased by absorption-promoting techniques, the effect of administration by injection is far from being achieved, and an oral preparation useful for clinical treatment cannot be obtained. For the immunoregulation active ingredients, a specific nano delivery tool is adopted, so that the oral absorption is improved, the functions of activating T cells and other immune cells in intestinal tracts and enhancing the immunotherapy effect are realized, and the preparation of an oral preparation for transferring tumors through lymph is developed.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a novel pharmaceutical application of a self-emulsifying delivery system, and particularly provides an application of the self-emulsifying delivery system containing an oil phase, an emulsifier, a co-emulsifier and an immunomodulator lipid material complex in preparing an oral medicament for treating lymphatic metastasis tumors.
In order to achieve the purpose, the invention adopts the following technical scheme:
the invention provides an application of a self-emulsifying delivery system in preparing an oral medicament for treating lymphatic metastasis tumor, wherein the self-emulsifying delivery system comprises an oil phase, an emulsifier, a co-emulsifier and an immunomodulator lipid material compound.
The self-emulsifying delivery system is a lipid carrier mainly composed of an oil phase, an emulsifying agent and an auxiliary emulsifying agent, can be diluted by gastrointestinal fluid and emulsified into an oil-in-water (o/w) nano-emulsion after being taken orally, is targeted and gathered in mesenteric lymph nodes through a lymph transport path, activates immune cells in the mesenteric lymph nodes, and finally exerts the immune effect of resisting tumors (particularly lymphatic metastasis tumors). The self-emulsifying delivery system can not only improve the compliance of patients, but also has more treatment advantages on tumors which are transferred by lymph, especially tumors which are sensitive to tumor immunotherapy.
Preferably, the lymphatic metastatic tumor is a tumor that can be treated by activating immune cells in the lymphatic system and/or lymphatic organs.
Preferably, the immune cells comprise any one or a combination of at least two of DC cells, T cells, B cells, NK cells or macrophages.
The combination of at least two of the above-mentioned combinations, such as the combination of DC cells and T cells, the combination of B cells and NK cells, the combination of NK cells and macrophages, etc., can be selected in any other combination manner, and is not repeated herein.
Preferably, the lymphoid metastatic tumour comprises brain glioma, lung cancer or leukaemia.
The brain glioma is the most common and fatal primary malignancy in the central nervous system, with a 5-year relative survival rate of less than 5%, and eventually relapses. The conventional therapy of brain glioma is to combine the resection with radiotherapy and temozolomide chemotherapy, and the effect is still not ideal. The limitations of conventional surgery are mainly due to the diffuse infiltrative nature of tumors, preventing complete resection of normal brain parenchymal infiltrating cells, and new therapies are urgently needed clinically to improve patient prognosis.
The incidence and mortality of lung cancer are high in the first place worldwide. Since early symptoms of lung cancer are not obvious, most patients have been diagnosed with locally diffuse or distant metastasis, leading to poor prognosis. Traditional therapies (surgery, radiation therapy and chemotherapy) have limited efficacy in controlling the progression of advanced lung cancer. Molecular targeted therapy is effective against specific molecular types of lung cancer, but acquired resistance usually occurs after 8-12 months of administration. The tumor immunotherapy, especially the related immune checkpoint inhibitor, has a rapid progress in the field of lung cancer treatment, and the adaptive syndrome is continuously approved at home and abroad, so that the tumor immunotherapy has an excellent clinical treatment prospect.
The leukemia is a hematological malignancy caused by differentiation disorder, apoptosis obstruction and clonal proliferation of hematopoietic stem cells at different differentiation stages, and the existing leukemia treatment methods comprise chemotherapy, radiotherapy, immunotherapy, targeted therapy, stem cell transplantation and the like. Leukemia is the first in the morbidity and mortality of malignant tumors in the population of 0-35 years old, and with the development of treatment methods, the complete remission rate is improved, but the recurrence rate is high. Immunotherapy of leukemia is based on the effect of a cell graft that can cure the disease on leukemia or can be defined as using the host's own cellular immunity against underlying disease, which can be accomplished by either enhancing the host's immune system or suppressing negative regulators. With the research and development of immunotherapy, the number of immune cells and immune pathways utilized by the immunotherapy is increasing, so that the clinical curative effect of leukemia is gradually improved.
The glioma, the lung cancer and the leukemia have high morbidity and mortality, poor prognosis and are easy to transfer through lymph.
Preferably, the emulsifier comprises any one or a combination of at least two of polyethylene glycol glyceride, caprylic/capric polyethylene glycol glyceride, oleic polyethylene glycol glyceride or linoleic polyethylene glycol glyceride; caprylic capric acid polyethylene glycol glyceride is preferred.
Compared with other types of emulsifiers, the caprylic capric acid polyethylene glycol glyceride as the emulsifier enables the finally formed self-emulsifying delivery system to have better emulsifying efficiency, tissue penetrability and safety, and further enables the self-emulsifying delivery system to have better absorption and lower gastrointestinal tract irritation in vivo.
The combination of at least two of the above-mentioned combinations, for example, the combination of macrogol glyceride and caprylic/capric macrogol glyceride, the combination of caprylic/capric macrogol glyceride and oleic macrogol glyceride, the combination of oleic macrogol glyceride and linoleic macrogol glyceride, etc., and any other combination mode can be selected, and thus, the description thereof is omitted.
Preferably, the coemulsifier comprises any one of propylene carbonate, ethylene glycol monoethyl ether, glycerol furfural, dimethyl isosorbide, diethylene glycol monoethyl ether, PEG400, glycerol or benzyl alcohol or a combination of at least two of them; a combination of dimethyl isosorbide and diethylene glycol monoethyl ether is preferred.
The combination of at least two of the above-mentioned compounds, such as the combination of propylene carbonate and ethylene glycol monoethyl ether, the combination of furfural glycerol and dimethyl isosorbide, the combination of glycerol and benzyl alcohol, etc., can be selected in any combination manner, and will not be described herein again.
Preferably, the oil phase comprises oleic acidEthyl ester, sorbitol oleate, glyceryl linoleate,1944cs, Maisine35-1, ethyl linoleate, C8/C10 monoglyceride, coconut oil C8/C10 diglyceride, coconut oil C8/C10 triglyceride, caprylic diglyceride, caprylic monoglyceride, capric diglyceride, capric triglyceride, caprylic capric monoglyceride, caprylic capric triglyceride, isopropyl myristate, linoleic acid macrogol glyceride, Gelucire or Capryol 90; a combination of ethyl oleate, sorbitol oleate and glyceryl oleate is preferred.
The combination of at least two of the above-mentioned compounds, for example, the combination of ethyl oleate and sorbitol oleate, the combination of glyceryl oleate and glyceryl linoleate, the combination of ethyl linoleate and C8/C10 monoglyceride, etc., may be selected in any combination manner, and thus, the details are not repeated herein.
Preferably, the immunomodulator lipid material complex consists of an immunomodulator and a lipid material, the molar ratio of the immunomodulator to the lipid material is 1 (0.25-8), such as 1:0.25, 1:0.5, 1:0.75, 1:1, 1:2, 1:3, 1:4, 1:6, 1:8 and the like, and any specific value in the numerical range can be selected, so that the details are not repeated. Preferably 1 (0.25-4).
Preferably, the complexing rate of the immunomodulator and the lipid material is greater than 90%, for example, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, etc., and any other specific value within the range of values can be selected, which is not described herein again.
Preferably, the immunomodulator comprises any one or combination of at least two of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, isochlorogenic acid A, isochlorogenic acid B, isochlorogenic acid C or silymarin; chlorogenic acid is preferred.
The combination of at least two of the chlorogenic acid and the neochlorogenic acid, the combination of the cryptochlorogenic acid and the isochlorogenic acid A, the combination of the isochlorogenic acid B and the isochlorogenic acid C, and the like can be selected in any combination mode, and are not described in detail herein.
Preferably, the lipid material comprises any one or a combination of at least two of soybean phospholipid, egg yolk phospholipid, phosphatidyl glycerol, distearoyl phosphatidylcholine, dipalmitoyl phosphatidylethanolamine, dimyristoyl phosphatidylcholine or ceramide; preferably a combination of soy phospholipids and egg phospholipids.
The combination of at least two of the above-mentioned components, such as the combination of soybean phospholipid and egg yolk phospholipid, the combination of phosphatidyl glycerol and distearoyl phosphatidylcholine, the combination of dipalmitoyl phosphatidylethanolamine and dimyristoyl phosphatidylcholine, etc., can be selected in any combination manner, and will not be described in detail herein.
Preferably, the content of the immunomodulator in the self-emulsifying delivery system is 5-200mg/g, such as 5mg/g, 10mg/g, 20mg/g, 50mg/g, 60mg/g, 80mg/g, 100mg/g, 120mg/g, 150mg/g, 180mg/g, 200mg/g, etc., and any specific value within the value range can be selected, and thus, the details are not repeated herein.
Preferably, the mass ratio of the oil phase, the emulsifier and the co-emulsifier is (1-5) to (3-6) to (2-6).
Wherein, the specific value in (1-5) can be 1, etc.
The specific values in (3-6) can be 3, 3.5, 4, 4.5, 5, 5.5, 6, etc.
The specific values in (2-6) can be 2, 3, 4, 5, 6, etc.
Other specific point values within the above numerical ranges can be selected, and are not described in detail herein.
Preferably, the medicament further comprises pharmaceutically acceptable auxiliary materials.
Preferably, the auxiliary materials comprise any one or a combination of at least two of a carrier, a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrating agent, an emulsifier, a cosolvent, a solubilizer, an osmotic pressure regulator, a surfactant, a coating material, a coloring agent, a pH regulator, an antioxidant, a bacteriostatic agent or a buffering agent.
The combination of at least two of the above components, such as the combination of a filler and a binder, the combination of an emulsifier and a cosolvent, the combination of an osmotic pressure regulator and a surfactant, the combination of a pH regulator and an antioxidant, and the like, can be selected in any combination manner, and are not described in detail herein.
Preferably, the carrier comprises a liposome, micelle, dendrimer, microsphere or microcapsule.
In the present invention, the self-emulsifying delivery system is prepared by a preparation method comprising the following steps:
mixing oil phase, emulsifier, co-emulsifier and lipid material complex of immunomodulator uniformly.
In the invention, the immune regulator lipid material compound is prepared by a preparation method comprising the following steps:
weighing immunomodulator and lipid material at a certain ratio, dissolving in organic solvent, mixing, standing for 15-30min (such as 15min, 17min, 20min, 22min, 25min, 28min, 30min, etc.), rotary evaporating or spray drying to remove organic solvent, and drying under reduced pressure.
Compared with the prior art, the invention has the following beneficial effects:
the self-emulsifying delivery system is a lipid carrier mainly composed of an oil phase, an emulsifying agent and an auxiliary emulsifying agent, can be diluted by gastrointestinal fluid and emulsified into an oil-in-water (o/w) nano-emulsion after being taken orally, is targeted and gathered in mesenteric lymph nodes through a lymph transport path, activates immune cells in the mesenteric lymph nodes, and finally exerts the immune effect of resisting tumors (particularly lymphatic metastasis tumors). The self-emulsifying delivery system can not only improve the compliance of patients, but also has more treatment advantages on tumors which are transferred by lymph, especially tumors which are sensitive to tumor immunotherapy (such as leukemia).
Drawings
FIG. 1 is a graph showing the volume results of in situ brain gliomas of each group of mice in test example 1 (wherein A is an observed nuclear magnetic resonance image and B is a statistical image of the volume of each group of tumors);
FIG. 2 is a graph showing statistics of CD40 and CD86 expression levels in mesenteric lymph nodes of each group of mice in test example 1;
FIG. 3 is a graph showing statistics of CD40 and CD86 expression levels in peripheral blood of each group of mice in test example 1;
FIG. 4 is a graph showing statistics of the proportion of central memory type CD3+ T cells in mesenteric lymph nodes of each group of mice in test example 1;
FIG. 5 is a graph showing the statistics of the analysis of immune cells in situ tumors of each group of mice in test example 1;
fig. 6 is an appearance of tumors of each group of mice in test example 3.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
The following method for determining the compounding rate of chlorogenic acid and lipid materials comprises the following steps:
(1) control solution: weighing a chlorogenic acid standard substance 25mg to 25ml volumetric flask, performing constant volume with ethanol solution, precisely weighing 1ml to 50ml volumetric flask, and performing constant volume with 30% ethanol water to obtain a reference substance solution;
(2)Wgeneral assembly: weighing 80mg of chlorogenic acid lipid material compound into a 25ml volumetric flask, carrying out constant volume shaking with absolute ethyl alcohol, precisely weighing 1ml to 50ml volumetric flask, and carrying out constant volume shaking with 30% ethanol water solution to obtain a total solution of a sample W;
(3)Wcompounding: weighing 80mg chlorogenic acid lipid material complex into 25mL volumetric flask, dissolving with chloroform, diluting to constant volume, filtering with 0.22 μm filter membrane, precisely weighing 1mL filtrate, blowing nitrogen to remove solvent (chloroform), diluting with 30% ethanol water to 50mL, and taking as sample WCompoundingAnd (3) solution.
Based on the above samples, the following HPLC conditions were used for the determination:
mobile phase: 0.4% phosphoric acid acetonitrile 82:18(v/v)
Detection wavelength: 328nm
Flow rate: 1.0mL/min
Column temperature: 25 deg.C
Sample introduction amount: 10 μ L
Stopping time: and 8 min.
The following method for determining the particle size of the self-emulsifying delivery system was used: 100 μ L of the self-emulsifying delivery system was added to 10mL of purified water, stirred for 1 minute, and the particle size was measured using a laser particle sizer.
The following method for determining the drug loading of a self-emulsifying delivery system was used: chromatography column packed with octadecylsilane bonded silica, Agilent SB-C18 (4.6X 250mm, 5 μm); mixing 1% glacial acetic acid: acetonitrile 90:10(v: v) is used as a mobile phase, and the detection wavelength is 328 nm; the column temperature was 25 ℃; the flow rate is 1 mL/min; sample introduction amount: 5 mu L of the solution; stopping time: and 15 min. Taking 833mg of a sample from an emulsion delivery system, precisely weighing, placing in a 10mL measuring flask, adding methanol for dissolving, diluting to a scale, shaking up, precisely weighing 1mL, placing in a 50mL measuring flask, diluting with methanol to a scale, and shaking up to obtain a test solution. Precisely weighing 10mg of chlorogenic acid reference substance, placing in a 10mL measuring flask, adding methanol for dissolving, diluting to scale, shaking, precisely weighing 1mL, placing in a 10mL measuring flask, adding solvent for diluting to scale, and shaking to obtain reference substance solution. And (4) measuring the solutions of the test sample and the reference substance, and calculating the content of the sample by peak area according to an external standard method.
Chlorogenic acids referred to below were purchased from ninthlo, Sichuan, Biotech, Inc.
The following ICR and C57BL/6 mice were purchased from Experimental animals technology, Inc., Viton, Beijing.
The following G422 cells, Lewis lung cancer cells and L1210 leukemia cells are all from the national cell resource center of the basic medical research institute of Beijing cooperative medical college.
Example 1
The invention provides a self-emulsifying delivery system, which is prepared by the following steps:
(1) taking soybean lecithin as a lipid material, feeding chlorogenic acid and the soybean lecithin according to a drug-lipid ratio of 1:1, adding the materials into a 1L round-bottom flask together, taking absolute ethyl alcohol as a solvent, controlling the drug concentration to be 60mg/ml, standing at 25 ℃ for 15min after the chlorogenic acid and the soybean lecithin are completely dissolved, then carrying out rotary evaporation at 100rpm and 40 ℃ in a rotary evaporator, carrying out reduced pressure drying to remove the absolute ethyl alcohol, and after the ethyl alcohol is evaporated to dryness, continuing to carry out reduced pressure drying at 100rpm at 25 ℃ for 1h to remove the ethyl alcohol completely, thus obtaining the chlorogenic acid lipid material compound. The recombination rate was determined to be 101.52% according to the above method.
(2) Weighing ethyl oleate, caprylic capric acid polyethylene glycol glyceride and diethylene glycol monoethyl ether according to the mass ratio of 2:5:3, and uniformly stirring and mixing to obtain a blank self-emulsifying concentrated solution.
(3) Adding the chlorogenic acid lipid material compound into the blank self-emulsifying concentrated solution according to the mass ratio of the compound to the blank self-emulsifying concentrated solution of 1.2:5, and placing the mixture into an air bath oscillator at the temperature of 25 ℃ and the rotating speed of 210rpm to obtain the self-emulsifying delivery system. The drug loading rate is measured to be 60mg/g, and the particle size is measured to be 60nm after the drug is diluted by 100 times of water.
Example 2
The invention provides a self-emulsifying delivery system, which is prepared by the following steps:
(1) taking soybean lecithin as a lipid material, feeding chlorogenic acid and the soybean lecithin according to a drug-lipid ratio of a molar ratio of 1:2, adding the chlorogenic acid and the soybean lecithin into a 1L round-bottom flask together, taking absolute ethyl alcohol as a solvent, controlling the drug concentration to be 60mg/ml, standing at 25 ℃ for 15min after the chlorogenic acid and the soybean lecithin are completely dissolved, then carrying out rotary evaporation at 100rpm and 40 ℃ in a rotary evaporator, carrying out reduced pressure drying to remove the absolute ethyl alcohol, drying the ethanol by evaporation, and continuing to carry out reduced pressure drying at 100rpm at 25 ℃ for 1h to remove the ethanol completely, thereby obtaining the chlorogenic acid-lipid material compound. The recombination rate was determined to be 100.89% according to the above method.
(2) Weighing ethyl oleate, caprylic capric acid polyethylene glycol glyceride and diethylene glycol monoethyl ether according to the mass ratio of 3:4:3, and uniformly stirring and mixing to obtain a blank self-emulsifying concentrated solution. And the antioxidant vitamin E (added in an amount of 0.04%) was added to the blank self-emulsifying concentrate.
(3) Adding the chlorogenic acid lipid material compound into the blank self-emulsifying concentrated solution according to the mass ratio of the compound to the blank self-emulsifying concentrated solution of 3.45:10, and placing the mixture into an air bath oscillator at the temperature of 25 ℃ and the rotating speed of 210rpm to obtain the self-emulsifying delivery system. The drug loading rate is measured to be 48mg/g, and the particle size is measured to be 100nm after the drug is diluted by 100 times of water.
Example 3
The present invention provides a self-emulsifying delivery system, the method of preparation of which differs from example 1 only in that: soybean lecithin was replaced with soybean lecithin and egg yolk lecithin in a mass ratio of 2:1 (the total amount of lipid material remained unchanged). Other conditions were kept consistent. The drug loading rate is measured to be 60mg/g, and the particle size is measured to be 50nm after 100 times of dilution by water.
Example 4
The present invention provides a self-emulsifying delivery system, the method of preparation of which differs from example 1 only in that: the diethylene glycol monoethyl ether was replaced with dimethyl isosorbide and diethylene glycol monoethyl ether in a mass ratio of 1:1 (the total amount of co-emulsifier was kept constant). Other conditions were kept consistent. The drug loading rate is measured to be 60mg/g, and the particle size is measured to be 60nm after the drug is diluted by 100 times of water.
Example 5
The present invention provides a self-emulsifying delivery system, the method of preparation of which differs from example 1 only in that: the ethyl oleate was replaced with ethyl oleate, sorbitol oleate and glycerol oleate in a mass ratio of 5:2:1 (the total amount of the oil phase remained unchanged). Other conditions were kept consistent. The drug loading rate is measured to be 60mg/g, and the particle size is measured to be 70nm after the drug is diluted by 100 times of water.
Example 6
The present invention provides a self-emulsifying delivery system, the method of preparation of which differs from example 1 only in that: the caprylic capric acid polyethylene glycol glyceride is replaced by linoleic acid polyethylene glycol glyceride with the same quantity. Other conditions were kept consistent. The drug loading rate is measured to be 60mg/g, and the particle size is measured to be 70nm after the drug is diluted by 100 times of water.
Test example 1
An ICR mouse inoculated with brain glioma in situ is taken as a model, and the construction method comprises the following steps: female ICR mice were anesthetized with sodium pentobarbital and placed in a stereotactic instrument. 2X 10 at a rate of 10. mu.L/min6One G422 cell was injected into the brain.
24 ICR mice (female, 18-20g) inoculated in situ with brain gliomas were randomly divided into 3 groups of 8 mice each, a model group, a CHA group and a CHA-SME group. Physiological saline, chlorogenic acid (CHA, intraperitoneal injection, 20 mg/kg/day, 9 consecutive days) and the sample of example 1 (CHA-SME, oral administration, 35 mg/kg/day, 9 consecutive days) were administered separately. After the administration, the tumor size in the mouse brain is observed by nuclear magnetic resonance to evaluate the anti-tumor effect of the chlorogenic acid self-emulsifying delivery system.
The experimental result is shown in figure 1 (wherein A is an observed nuclear magnetic resonance image, and B is a statistical image of the tumor volume of each group), and the chlorogenic acid self-emulsifying delivery system (CHA-SME) can obviously inhibit the growth of the brain glioma in situ of the mouse at the dosage of 35 mg/kg. Compared with the model group, the tumor volumes of the chlorogenic acid (CHA) and the chlorogenic acid self-emulsifying delivery system (CHA-SME) are respectively reduced to 54 percent and 46 percent, which indicates that the chlorogenic acid self-emulsifying delivery system (CHA-SME) has stronger tumor inhibition effect.
The mice were subjected to immunoassays for mesenteric lymph nodes, peripheral blood and in situ tumors after administration, including mainly DC and T cell analysis. Experimental results as shown in fig. 2 and 3, characteristic mature proteins of DC surface in mesenteric lymph nodes and peripheral blood were significantly up-regulated compared to the model group after administration of chlorogenic acid self-emulsifying delivery system (CHA-SME). As shown in fig. 2, CD40 and CD86 were increased 2.4 and 1.4 fold, respectively, in the mesenteric lymph nodes of the chlorogenic acid self-emulsifying delivery system (CHA-SME) group compared to the model group, whereas no significant change was observed in the chlorogenic acid (CHA) group. Furthermore, the CD86 in mesenteric lymph nodes of the chlorogenic acid self-emulsifying delivery system (CHA-SME) group was 1.4 times higher than that of the chlorogenic acid (CHA) group. As shown in fig. 3, CD40 and CD86 in peripheral blood of the chlorogenic acid self-emulsifying delivery system (CHA-SME) group were increased by 1.3 and 13.4 times, respectively, compared to the model group, while no significant change was observed in the chlorogenic acid (CHA) group. In addition to stimulating DC maturation, as shown in FIG. 4, the ratio of central memory CD3+ T cells in mesenteric lymph nodes was increased 1.6 fold in the chlorogenic acid self-emulsifying delivery system (CHA-SME) group compared to the model group, whereas no significant change was observed in the chlorogenic acid (CHA) group.
Results of immunocytoanalysis in situ tumors as shown in fig. 5, the chlorogenic acid self-emulsifying delivery system (CHA-SME) group can significantly up-regulate the proportion of T cells (including CD3+, CD4+, CD8+, and memory T cells) in tumor tissues, compared to the model group and the chlorogenic acid (CHA) group. Compared with the chlorogenic acid (CHA) group, the tumor immunotherapy effect of the T cells is enhanced by 1.3, 2.4, 4.1, 1.6, 3.0, 4.1, 3.7 and 3.8 times respectively for CD3+, CD4+, CD8+, effector memory CD3+ T cells, effector memory CD4+ T cells, central memory CD4+ T cells, effector memory CD8+ T cells and central memory CD8+ T cells in the tumor tissues of the chlorogenic acid self-emulsifying delivery system (CHA-SME) group.
Test example 2
An ICR mouse with subcutaneous brain glioma transplantation is taken as a model, and the construction method comprises the following steps: 2 x 10 to6One G422 cell was injected subcutaneously into the right forelimb underarm area of female ICR mice.
18 ICR mice (female, 18-20g) with subcutaneously transplanted brain gliomas were randomly divided into 3 groups of 6 mice each, model, CHA and CHA-SME groups.
Physiological saline, chlorogenic acid (CHA, oral, 35 mg/kg/day, 19 consecutive days) and the sample of example 2 (CHA-SME, oral, 35 mg/kg/day, 19 consecutive days) were administered separately. Subcutaneous tumors were stripped and weighed after dosing to evaluate tumor suppression.
The experimental results are shown in table 1, compared with the model group and chlorogenic acid, the chlorogenic acid self-emulsifying delivery system (CHA-SME) can obviously inhibit the growth of the brain glioma of the mouse at the dosage of 35 mg/kg.
TABLE 1
Group of | Tumor weight (g) |
Model set | 2.28±0.71 |
CHA group | 2.40±0.21 |
CHA-SME group | 0.82±0.55 |
Test example 3
The construction method takes a Lewis lung cancer C57BL/6 mouse transplanted under the skin as a model and comprises the following steps: will be 5X 105One Lewis lung carcinoma cell was injected subcutaneously into the right hind limb of male C57BL/6 mice.
6 Lewis lung carcinoma C57BL/6 mice (male, 16-18g) implanted subcutaneously were randomly divided into 2 groups of 3, a model group and a CHA-SME group.
Physiological saline, the sample of example 1 (CHA-SME, oral, 30 mg/kg/day, 14 consecutive days) were administered separately. Subcutaneous tumors were stripped and weighed after dosing to evaluate tumor suppression.
The experimental results are shown in fig. 6, compared with the model group, the chlorogenic acid self-emulsifying delivery system (CHA-SME) can significantly inhibit the growth of the lung cancer of the mice at the dosage of 30 mg/kg.
Test example 4
The construction method takes a subcutaneously transplanted L1210 leukemia DBA/2 mouse as a model and comprises the following steps: will be 6X 105One L1210 leukemia cell was injected subcutaneously into the right hind limb medial side of female DBA/2 mice.
48 ICR mice (female, 18-20g) were randomly divided into 8 groups of 6 mice each, model, CHA low, CHA high and CHA-SME 1-5 groups, respectively.
Chlorogenic acid (CHA, intraperitoneal injection, 20 and 40 mg/kg/day, continuous administration for 12 days) and the samples prepared in examples 1, 3-6 (CHA-SME, oral administration, 35 mg/kg/day, continuous administration for 12 days) were administered sequentially and separately. Subcutaneous tumors were stripped and weighed after dosing to evaluate tumor suppression.
The experimental results are shown in table 2, compared with the model group, the oral chlorogenic acid self-emulsifying delivery system (CHA-SME) can significantly inhibit the growth of murine leukemia, the tumor growth inhibition rate is more than 44.4%, and the tumor growth inhibition rate is respectively 29.8% and 40.5% better than that of the chlorogenic acid intraperitoneal injection group (20 and 40 mg/kg). Meanwhile, the data in the table show that the selection of the emulsifier, the co-emulsifier, the oil phase and the lipid material in the self-emulsifying delivery system can influence the anti-leukemia effect.
TABLE 2
Group of | Tumor weight (g) |
Model set | 2.70±0.40 |
CHA Low dose group | 1.90±0.75 |
CHA high dose group | 1.61±0.90 |
CHA- |
1.40±0.25 |
CHA- |
0.95±0.20 |
CHA-SME 3 group (example 4) | 1.05±0.15 |
CHA-SME 4 group (example 5) | 1.10±0.30 |
CHA-SME 5 group (example 6) | 1.50±0.10 |
The applicant states that the invention is illustrated by the above examples of the use of a self-emulsifying delivery system of the invention for the preparation of an oral medicament for the treatment of lymphatic metastases, but the invention is not limited to the above examples, i.e. it is not intended that the invention must be practiced in reliance thereon. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. Use of a self-emulsifying delivery system for the manufacture of an oral medicament for the treatment of lymphatic metastases, characterized in that the self-emulsifying delivery system comprises an oil phase, an emulsifier, a co-emulsifier and an immunomodulator lipid material complex.
2. The use of claim 1, wherein the lymphatic metastatic tumor is a tumor that can be treated by activating immune cells in the lymphatic system and/or lymphatic organs;
preferably, the immune cells comprise any one or a combination of at least two of DC cells, T cells, B cells, NK cells or macrophages;
preferably, the lymphoid metastatic tumour comprises brain glioma, lung cancer or leukaemia.
3. The use of claim 1 or 2, wherein the emulsifier comprises any one of or a combination of at least two of macrogol glyceride, caprylic/capric macrogol glyceride, oleic macrogol glyceride or linoleic macrogol glyceride; caprylic capric acid polyethylene glycol glyceride is preferred.
4. The use of any one of claims 1 to 3, wherein the co-emulsifier comprises any one or a combination of at least two of propylene carbonate, ethylene glycol monoethyl ether, glycerol furfural, dimethyl isosorbide, diethylene glycol monoethyl ether, PEG400, glycerol or benzyl alcohol; a combination of dimethyl isosorbide and diethylene glycol monoethyl ether is preferred.
5. The use of any one of claims 1 to 4, wherein the oil phase comprises ethyl oleate, sorbitol oleate, glycerol linoleate, glycerol,1944cs, Maisine35-1, ethyl linoleate, C8/C10 monoglyceride, coconut oil C8/C10 diglyceride, coconut oil C8/C10 triglyceride, caprylic diglyceride, caprylic monoglyceride, capric diglyceride, capric triglyceride, caprylic capric monoglyceride, caprylic capric triglyceride, isopropyl myristate, linoleic acid macrogol glyceride, Gelucire or Capryol 90; a combination of ethyl oleate, sorbitol oleate and glyceryl oleate is preferred.
6. The use according to any one of claims 1 to 5, wherein the immunomodulatory lipid material complex consists of an immunomodulatory agent and a lipid material, the molar ratio of immunomodulatory agent to lipid material being 1 (0.25-8), preferably 1 (0.25-4);
preferably, the complexing rate of the immunomodulator with the lipid material is greater than 90%;
preferably, the immunomodulator comprises any one or combination of at least two of chlorogenic acid, neochlorogenic acid, cryptochlorogenic acid, isochlorogenic acid A, isochlorogenic acid B, isochlorogenic acid C or silymarin; preferably chlorogenic acid;
preferably, the lipid material comprises any one or a combination of at least two of soybean phospholipid, egg yolk phospholipid, phosphatidyl glycerol, distearoyl phosphatidylcholine, dipalmitoyl phosphatidylethanolamine, dimyristoyl phosphatidylcholine or ceramide; preferably a combination of soy phospholipids and egg phospholipids.
7. The use of any one of claims 1 to 6, wherein the amount of immunomodulator in the self-emulsifying delivery system is from 5 to 200 mg/g;
preferably, the mass ratio of the oil phase, the emulsifier and the co-emulsifier is (1-5) to (3-6) to (2-6).
8. The use of any one of claims 1-7, wherein the medicament further comprises a pharmaceutically acceptable excipient;
preferably, the auxiliary materials comprise any one or a combination of at least two of a carrier, a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrating agent, an emulsifier, a cosolvent, a solubilizer, an osmotic pressure regulator, a surfactant, a coating material, a coloring agent, a pH regulator, an antioxidant, a bacteriostatic agent or a buffering agent.
9. Use according to any one of claims 1 to 8, wherein the self-emulsifying delivery system is prepared by a preparation method comprising the steps of:
mixing oil phase, emulsifier, co-emulsifier and lipid material complex of immunomodulator uniformly.
10. The use of claim 9, wherein the immunomodulatory lipid material complex is prepared by a method comprising:
weighing immunomodulator and lipid material according to a certain proportion, dissolving in organic solvent, mixing, standing for 15-30min, removing organic solvent by rotary evaporation or spray drying, and drying under reduced pressure.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110784259.XA CN113509439A (en) | 2021-07-12 | 2021-07-12 | Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110784259.XA CN113509439A (en) | 2021-07-12 | 2021-07-12 | Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113509439A true CN113509439A (en) | 2021-10-19 |
Family
ID=78066624
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110784259.XA Pending CN113509439A (en) | 2021-07-12 | 2021-07-12 | Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113509439A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114469895A (en) * | 2022-03-14 | 2022-05-13 | 海南大学 | Preparation method of metal polyphenol nano-vaccine for delivering antigen and immune environment regulator and product obtained therefrom |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622864A (en) * | 2015-02-13 | 2015-05-20 | 四川九章生物科技有限公司 | Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma |
CN110179750A (en) * | 2019-06-17 | 2019-08-30 | 四川九章生物科技有限公司 | A kind of chlorogenic acid self-emulsifying composition and application thereof |
-
2021
- 2021-07-12 CN CN202110784259.XA patent/CN113509439A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104622864A (en) * | 2015-02-13 | 2015-05-20 | 四川九章生物科技有限公司 | Application of chlorogenic acid in preparing drugs for prevention and treatment of primary cutaneous T-cell lymphoma |
CN110179750A (en) * | 2019-06-17 | 2019-08-30 | 四川九章生物科技有限公司 | A kind of chlorogenic acid self-emulsifying composition and application thereof |
Non-Patent Citations (2)
Title |
---|
杨晓丽等: "绿原酸抗肿瘤作用及机制研究进展", 《中国实验方剂学杂志》 * |
陆彬等: "《药剂学》", 31 January 2003, 中国医药科技出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114469895A (en) * | 2022-03-14 | 2022-05-13 | 海南大学 | Preparation method of metal polyphenol nano-vaccine for delivering antigen and immune environment regulator and product obtained therefrom |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8765181B2 (en) | Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids | |
US5225404A (en) | Methods of treating colon tumors with tumor-inhibiting camptothecin compounds | |
CN102784109B (en) | Taxane medicines albumin nanoparticle preparation for injection and preparation method thereof | |
EP1359909B1 (en) | Triptolide prodrugs for anti-cancer therapy | |
WO2018035884A1 (en) | Drug combination having anti-tumor efficacy | |
CN113509439A (en) | Application of self-emulsifying delivery system in preparation of oral medicine for treating lymphatic metastasis tumor | |
CN101601648A (en) | Sub-microemulsion used for intravenous injection of polyene yew alcohol phospholipid composite and preparation method thereof | |
CN109700799A (en) | Antrocin and its micro-nano granules are preparing the application in immunotherapy of tumors drug | |
AU743137B2 (en) | Intra-cancer-cell nuclease activator | |
CN111281869B (en) | Application of melatonin in the preparation of medicaments for the treatment and adjuvant treatment of osteosarcoma | |
WO2007131365A1 (en) | Treatment of neoplastic disorders using a farnesyl dibenzodiazepinone administered by continuous intravenous infusion | |
WO2013082839A1 (en) | Drug-loaded liposome for overcoming tumor drug resistance, method for preparing same, and application thereof | |
JP4711947B2 (en) | Taxanes and other antitumor agents encapsulated in stable filter-sterilized liposomes | |
CN100594902C (en) | Nanomicelle preparation of vinca alkaloid antineoplastic drugs entrapped in polyethylene glycol derivatized phospholipids | |
Supersaxo et al. | The antitumour effect of lipophilic derivatives of 5-fluoro-2'-deoxyuridine incorporated into liposomes | |
CN101138548B (en) | Polyglycol derivatization phospholipid loaded vinorelbine nano-micelle preparations | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
KR102694803B1 (en) | Combination of A-nor-5α-androstane compound drugs and anticancer agents | |
CN106176608A (en) | Pemetrexed disodium injection and preparation method thereof | |
CN106822099A (en) | The medicinal composition for injections that vitamin C acts synergistically with benzenesulfonamide compounds | |
EP4349338A1 (en) | Treatment agent | |
EP4349337A1 (en) | Anti-tumor agent | |
CN116803393B (en) | Pharmaceutical composition of pan-HER inhibitor and preparation method thereof | |
CN1743337B (en) | Taxol derivative and its pharmaceutical composition | |
CN102716085B (en) | Topotecan hydrochloride liposome injection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |